Laura Chico
Stock Analyst at Wedbush
(3.73)
# 725
Out of 5,134 analysts
232
Total ratings
49.06%
Success rate
8.24%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Reiterates: Neutral | $25 | $20.45 | +22.25% | 15 | Feb 17, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $149 → $151 | $126.00 | +19.84% | 11 | Feb 12, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $46 → $55 | $48.00 | +14.60% | 12 | Feb 11, 2026 | |
| BIIB Biogen | Maintains: Neutral | $178 → $187 | $197.57 | -5.35% | 20 | Feb 10, 2026 | |
| ARDX Ardelyx | Maintains: Outperform | $16 → $19 | $6.89 | +175.76% | 15 | Jan 21, 2026 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $32 → $36 | $31.91 | +12.82% | 9 | Jan 12, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $83 → $95 | $317.25 | -70.06% | 11 | Jan 12, 2026 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $31 → $30 | $18.96 | +58.27% | 10 | Dec 11, 2025 | |
| VERA Vera Therapeutics | Maintains: Neutral | $23 → $33 | $42.30 | -21.99% | 9 | Dec 11, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $42 → $47 | $28.12 | +67.17% | 8 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $30 | $26.45 | +13.42% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $36 | $46.01 | -21.76% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $32 | $29.89 | +7.06% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $11 | $3.18 | +245.91% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $6.38 | +25.39% | 12 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $18 | $15.03 | +19.76% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $6.07 | +130.83% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $41.48 | +3.66% | 9 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $27.20 | +17.65% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.28 | +119.30% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $6.79 | +165.29% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $16.89 | -76.32% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.41 | +112.77% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $21.99 | +31.88% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.38 | +107.10% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $88 | $4.55 | +1,834.07% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $10.08 | -50.40% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $59.99 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $4.53 | +10.50% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $11.23 | +1,222.35% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $7.56 | +9,423.81% | 1 | Jan 19, 2018 |
Ultragenyx Pharmaceutical
Feb 17, 2026
Reiterates: Neutral
Price Target: $25
Current: $20.45
Upside: +22.25%
Neurocrine Biosciences
Feb 12, 2026
Maintains: Outperform
Price Target: $149 → $151
Current: $126.00
Upside: +19.84%
Dianthus Therapeutics
Feb 11, 2026
Maintains: Outperform
Price Target: $46 → $55
Current: $48.00
Upside: +14.60%
Biogen
Feb 10, 2026
Maintains: Neutral
Price Target: $178 → $187
Current: $197.57
Upside: -5.35%
Ardelyx
Jan 21, 2026
Maintains: Outperform
Price Target: $16 → $19
Current: $6.89
Upside: +175.76%
Stoke Therapeutics
Jan 12, 2026
Maintains: Outperform
Price Target: $32 → $36
Current: $31.91
Upside: +12.82%
Praxis Precision Medicines
Jan 12, 2026
Maintains: Underperform
Price Target: $83 → $95
Current: $317.25
Upside: -70.06%
Denali Therapeutics
Dec 11, 2025
Maintains: Outperform
Price Target: $31 → $30
Current: $18.96
Upside: +58.27%
Vera Therapeutics
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $42.30
Upside: -21.99%
Viridian Therapeutics
Dec 10, 2025
Maintains: Outperform
Price Target: $42 → $47
Current: $28.12
Upside: +67.17%
Nov 13, 2025
Maintains: Outperform
Price Target: $27 → $30
Current: $26.45
Upside: +13.42%
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $36
Current: $46.01
Upside: -21.76%
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $29.89
Upside: +7.06%
Sep 30, 2025
Maintains: Outperform
Price Target: $15 → $11
Current: $3.18
Upside: +245.91%
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $6.38
Upside: +25.39%
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $15.03
Upside: +19.76%
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $6.07
Upside: +130.83%
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $41.48
Upside: +3.66%
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $27.20
Upside: +17.65%
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.28
Upside: +119.30%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $6.79
Upside: +165.29%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $16.89
Upside: -76.32%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.41
Upside: +112.77%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $21.99
Upside: +31.88%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.38
Upside: +107.10%
Apr 11, 2024
Maintains: Outperform
Price Target: $104 → $88
Current: $4.55
Upside: +1,834.07%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $10.08
Upside: -50.40%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $59.99
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $4.53
Upside: +10.50%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $11.23
Upside: +1,222.35%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $7.56
Upside: +9,423.81%